

. 103-29-01

· CERTIFICATE OF EXPRESS MAIL

Express Mail No.: <u>EL611000467US</u>
Date of Deposit: <u>March 20, 2001</u>



**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: MXGN:005USC2

**Prior Application Examiner:** 

P. Do

**BOX PATENT APPLICATION** 

Commissioner for Patents Washington, D.C. 20231

**Classification Designation:** 

**Prior Group Art Unit: 1641** 

## REQUEST FOR FILING CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

This is a request for filing a continuation application under Rule 53(b) (37 C.F.R. § 1.53(b)) of co-pending prior application Serial No. 08/847,063 filed May 1, 1997, entitled "DIRECTED EVOLUTION OF ENZYMES AND ANTIBODIES."

Enclosed is a copy of the prior application Serial No. 08/847,063 as originally filed, including specification, claims, drawings, and declaration. The undersigned hereby verifies that the attached papers are a true copy of the prior application as originally filed and identified above, that no amendments (if any) referred to in the declaration filed to complete the prior application introduced new matter therein, and further that this statement was made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such

	willful	willful false statement may jeopardize the validity of the application or any patent					
	issuing	issuing thereon.					
	(a)	$\boxtimes$	The inventorship is the same as prior Application Serial No.				
			08/847,063.				
	(b)		Deletion of inventor(s). Signed statement attached deleting				
			inventor(s) named in the prior application, see 37 C.F.R. § 1.63(d)(2)				
			and 1.33(b).				
•	(c)		Priority of foreign patent application number , filed in				
			is claimed under 35 U.S.C. § 119(a)-(e). The certified copy:				
			is enclosed.				
			has been filed in the prior Application Serial No.				
	The Co	The Commissioner is requested to grant Applicants a filing date in accordance					
	with R	Rule 1.:	le 1.53, and supply Applicants with a Notice of Missing Parts in due				
	course	course, in accordance with the provisions of Rule 1.53(f).					
<u> </u>	Enclos	Enclosed is a check in the amount of \$ to cover the filing fee as calculated					
	below	below and the fee for any new claims added in the Preliminary Amendment					
	referre	referred to in Part No. 9 below.					

# CLAIMS AS FILED IN THE PRIOR APPLICATION LESS CLAIMS CANCELED BELOW

FOR		NUMBER FILED	NUMBER EXTRA	RATE	FEE				
Basic	Fee				\$710.00				
Total Claims Independent Claims Multiple Depe		- 20 = - 3 = endent Claim(s)	X X	\$18.00 = \$80.00 =	\$ .00 \$ .00 \$-000				
FOR		NUMBER FILED	TOTAL FILING F NUMBER EXTRA	FEES: RATE	\$ .00 FEE				
$\boxtimes$	4.	Applicant is entitled to Small Entity Status for this application.							
		(a) A small entity st	atement is enclosed.						
$\boxtimes$		(b) A small entity statement was filed in the prior nonprovisional application a							
		such status is sti	ll proper and desired.						
		(c) Small entity sta	tus is no longer claim	ed.					
	5.	If the check is missing or insufficient, the Commissioner is hereby authorized to							
		charge any fees under 37 C.F.R. §§ 1.16 to 1.21 which may be required for a							
		reason relating to this	application, or cred	lit any overpayment to	o Fulbright &				
		Jaworski L.L.P. Account No.: 50-1212/08001973/SLH.							
	6.	Enclosed is a copy of the current Power of Attorney in the prior application.							
$\boxtimes$	7.	Address all future comm	nunications to:						
			k JAWORSKI L.L.P. Avenue, Suite 2400						

 $\boxtimes$ 8. The prior application is presently assigned to Board of Regents, The University of Texas System. 9. Enclosed is a preliminary amendment. Any additional fees incurred by this amendment are included in the check at No. 3 above and said fee has been calculated after calculation of claims and after amendment of claims by the preliminary amendment. Cancel in this application claims of the prior application before calculating 10. the filing fee. (At least one original independent claim must be retained). Amend the specification by inserting before the first line the sentence: -- This is a  $\boxtimes$ 11. continuation of co-pending application Serial No. 08/847,063 filed May 1, 1997--. Enclosed are formal drawings. 12.  $\prod$ 13. An Information Disclosure Statement (IDS) is enclosed.  $\Box$ (a) PTO-1449. Copies of IDS citations. (b) Transfer the sequence information, including the computer readable form previously M 14. submitted in the parent application, Serial No. 08/847,063 filed May 1, 1997, for use in this application. Under 37 C.F.R. § 1.821(e), Applicants state that the paper copy of the sequence listing in this application is identical to the computer readable copy in parent application Serial No. 08/847,063 filed May 1, 1997. Under 37 C.F.R. § 1.821(f), Applicants also state that the information recorded in computer readable form is identical to the written sequence listing.

 $\boxtimes$ 

15.

Other: Request For Transfer of Sequence Listing Under 37 C.F.R. 1.821(e).

Respectfully submitted,

Steven L'Aighlander

Reg. No. 37,642

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3184

Date:

March 20, 2001

CERTIFICATE OF EXPRESS MAIL

Express Mail No.: <u>EL564337576US</u>
Date of Deposit: March 20, 2001

PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brent Iverson, George Georgiou and Gang Chen

Serial No.: 08/847,063

Filed: May 1, 1997

For: DIRECTED EVOLUTION OF ENZYMES

AND ANTIBODIES

Group Art Unit: 1641

Examiner: P. Do

Atty. Dkt. No.: MXGN:005USC2

### REQUEST FOR TRANSFER OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821(e)

#### **BOX SEQUENCE**

Commissioner for Patents Washington, D.C. 20231

Commissioner:

Pursuant to 37 C.F.R. § 1.821(e), Applicants respectfully request that the sequence information previously submitted in parent application ("parent application"), U.S. Serial No. 08/847,063 filed May 1, 1997, be transferred to and used in the above-referenced patent application ("instant application"). Only one computer readable sequence listing was submitted to the U.S. Patent and Trademark Office in the parent application. The sequence information in the instant application is identical to the sequence information contained in the previously-filed computer readable sequence listing in the parent application. It is understood that the U.S. Patent and Trademark Office will make the necessary change in application number and filing date of

the computer readable form that will be used for the instant application. A paper copy of the sequence listing is included in the originally-filed specification of the instant application.

Applicants request the transfer of the previously-filed computer readable sequence listing from the parent application to the instant application is in lieu of filing a duplicate computer readable sequence listing.

No fee is believed to be due in connection with the filing of this document; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski Account No.: 50-1212/08001973/SLH.

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3184

Date:

March 20, 2001